Genetic markers linked to the start of symptoms of Parkinson's disease

September 27, 2019

Researchers from the Institute of Neurosciences of the University of Barcelona (UBNeuro), Hospital Clínic and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) have identified a group of genetic variants related to the starting point of Parkinson's disease. These results, published in the journal Movement Disorders, will enable delimiting the research on new therapeutic targets, and could have implications in the diagnosis of the disease.

The study has been led by the lecturer of the Department of Biomedicine of the Faculty of Medicine and Health Sciences of the UB Cristina Malagelada, as well as Maria Josep Martí, head of the Unit of Parkinson's and Movement Disorders at Hospital Clinic, and Mario Ezquerra and Rubén Fernández Santiago, geneticists at IDIBAPS. Núria Martín-Flores, UBNeuro researcher, is the first signer of the article, which was been fully funded by the Michael J. Fox Foundation for Parkinson's Research (United States).

Association between genetic markers

Researchers studied genetic markers -DNA segments with chromosome-identifiable locations- that adjust the starting age of the Parkinson's disease. "There are known genetic markers, such as the genetic markers of the synuclein gene, which are associated with an earlier start of the symptoms, but in this study we focused on the influence of the association of other markers which were not known yet", says Cristina Malagelada, UBNeuro researcher.

The results, obtained from blood samples from more than 900 patients of Hospital Clinic, show that a group of genetic markers of the mTOR metabolic pathway, combined and not individually, contribute to adjust the starting age of the Parkinson's disease. "Identifying this group of markers that influence each other and which condition the starting point of the disease allow delimiting the research of new therapeutic targets in these candidate genes", highlights Cristina Malagelada.

Also, the identification of this gene family -linked to the neuronal survival, synaptic plasticity and protein synthesis- has been confirmed in an independent second population of affected patients of about 4,000 people, obtained thanks to the collaboration with the International Parkinson Disease Genomic Consortium.

According to the UB researcher, this study, which used Biocomputing techniques, shows the importance of the analysis of statistical interactions to identify genetic associations, since it can help explain complex diseases such as neurodegenerative ones.

The second most common neurodegenerative disease

Parkinson's disease, which affects more than 1% of the population, is the second most common neurodegenerative disease after Alzheimer's. It affects more than six million people worldwide, a figure that could get over twelve millions by 2030, according to data from the World Health Organization (WHO). In this pathology, the neurotransmitter that controls motor activity -dopamine- is reduced due the progressive death of dopaminergic neurons.
-end-


University of Barcelona

Related Neurodegenerative Articles from Brightsurf:

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

AI-analyzed blood test can predict the progression of neurodegenerative disease
A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

New study sheds light into origins of neurodegenerative disease
New research has shed light on the origins of spinocerebellar ataxia type 7 (SCA7) and demonstrates effective new therapeutic pathways for SCA7 and the more than 40 other types of spinocerebellar ataxia.

How mutations lead to neurodegenerative disease
Scientists have discovered how mutations in DNA can cause neurodegenerative disease.

Protein complex may help prevent neurodegenerative diseases
The protein complex NAC in the cell helps to prevent the aggregration of proteins associated with several neurodegenerative diseases.

Circadian clock plays unexpected role in neurodegenerative diseases
Northwestern University researchers induced jet lag in a fruit fly model of Huntington disease and found that jet lag protected the flies' neurons.

Neurodegenerative diseases identified using artificial intelligence
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative disease in human brain tissue samples, including Alzheimer's disease and chronic traumatic encephalopathy.

Read More: Neurodegenerative News and Neurodegenerative Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.